MEC PROTOKOLÜ

Kaynaklar:

1-Tallman MS, Lee S, Sikic BI, et al. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia. Cancer. 1999;85:358–67

2- Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: An effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol. 1991;9:1210–4.

3-Tribalto M, Cantonetti M, Catalano G, et al. Mitoxantrone in combination with etoposide and cytarabine for treatment of poor prognosis acute non lymphoid leukemia patients. Haematologica. 1991;76:402–5.

4-Shepherd JD, Reece DE, Barnett MJ, et al. Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone, and etoposide. Leuk Lymphoma. 1993;9:211–5

5-Thol F, Schlenk R, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood 2015; 126:319–327.

6-Choi Y, Lee J, Lee K, et al. Treatment outcomes and prognostic factors of patients with relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood 2016; 128:4004. 

7-Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129:424–447.

8-Westhus J, Noppeney R, Dührsen U, Hanoun M. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 2019; 60:1014–1022.

9-Parker J, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997; 99:939–944.

10-Spadea A, Petti M, Fazi P, et al. Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. Leukemia 1993; 7:549–552.